September 29, 2010 — In a prospective study published in the European Journal of Nuclear Medicine and Molecular Imaging, researchers at Boca Raton Regional Hospital, Boca Raton, Fla., showed that positron emission mammography (PEM) and breast magnetic resonance imaging (MRI) had a comparably high ability to detect cancerous lesions.

The prospective study enrolled 182 women with recent biopsy-proven primary breast cancer. It also found that PEM was not impacted by menopausal status, breast density or hormone replacement therapy, making PEM a valuable alternative.

PEM scanners are high-resolution breast positron emission tomography (PET) systems that show the location as well as the metabolic phase of a lesion. The metabolic view assists physicians to make the optimal cancer care decision by providing an unprecedented ability to distinguish between benign and malignant lesions, what researchers term “specificity.” PEM is different from X-ray mammography in that it is currently not used as a screening modality, rather is deployed to confirm extent of disease in a patient already diagnosed with a primary breast cancer.

“We were very pleased to find that PEM and MRI had comparable ability to detect cancerous lesions regardless of type or severity of the tumor,” said Kathy Schilling, M.D., lead author on the study. “In addition, the data showed that PEM is a fantastic alternative for women with dense breasts or where timing of an MRI due to menstrual cycle is challenging. The next step is to understand how PEM and MRI compare when differentiating between benign and malignant suspicious lesions.”

Results from a separate NIH-sponsored clinical study (NIH Grant 5R44CA103102), recently presented at the 2010 Society of Nuclear Medicine Annual Meeting, comparing PEM and breast MRI help answer Dr. Schilling’s question. The multi-site study of hundreds of women with newly diagnosed breast cancer shows that PEM demonstrated a 6 percent improvement in specificity, ability to differentiate between malignant and benign lesions, suggesting that PEM may reduce unnecessary biopsies. These results are particularly significant for women who cannot tolerate an MRI exam and require an alternate imaging tool. The study is slated for publication in the December issue of the journal Radiology.

For more information: naviscan.com


Related Content

News | Digital Radiography (DR)

July 10, 2025 — Fujifilm Healthcare Americas Corp. has launched several advanced automated functions for its FDR ...

Time July 10, 2025
arrow
News | Breast Imaging

July 8, 2025 — QT Imaging Holdings, has appointed Elaine Iuanow, MD, as chief medical officer (CMO) and Kim Du as senior ...

Time July 09, 2025
arrow
News | Breast Imaging

July 7, 2025 — SimonMed Imaging, one of the largest outpatient medical imaging providers in the United States, has ...

Time July 08, 2025
arrow
News | Computed Tomography (CT)

July 01, 2025 — NANO-X Imaging Ltd. recently announced a clinical and educational collaboration with Keiser University ...

Time July 03, 2025
arrow
News | Ultrasound Imaging

June 26, 2025 — FUJIFILM VisualSonics Inc., a provider of ultra-high frequency ultrasound and photoacoustic imaging ...

Time June 27, 2025
arrow
News | Prostate Cancer

June 26, 2025 – Quibim, a global provider of quantitative medical imaging solutions, has launched AI-QUAL, a new feature ...

Time June 26, 2025
arrow
News | Breast Imaging

June 25, 2025 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time June 25, 2025
arrow
News | Imaging Software Development

June 12, 2025 — GE HealthCare has announced the combination of GE HealthCare’s proprietary features and algorithms with ...

Time June 12, 2025
arrow
News | PET Imaging

May 30, 2025 — GE HealthCare recently announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) ...

Time May 30, 2025
arrow
News | Radiology Business

The issue of sustainability in healthcare has gained increasing focus over the past several years. During a 2022 plenary ...

Time May 06, 2025
arrow
Subscribe Now